Health Economics›Pancreatic cancer›Metastatic disease second-line

Metastatic disease second-line

Pancreatic cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	5.9 mo	7	R 11 705 PFS proxy	1
Capecitabine monotherapy Variant #01	—	R 1 039	21d	—	—	2	R 2 077 PFS proxy	2
Sotorasib monotherapy Variant #01 Partial	—	—	28d	~5.6 mo	—	~2	—	1

3 of 3 regimens shown